4 – Alzheimers

NEW YORK, June 15, 2011 /PRNewswire-USNewswire/ — The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) invite scientists from academia and the biotechnology industry worldwide to apply for research grants to develop Frontotemporal Dementia (FTD)-specific biomarkers that reflect pathological and clinical differences so that appropriate …

See ... continue reading

The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer’s Disease.

Read the original:
... continue reading

The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $240,000 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment (aMCI), a neurological condition that often progresses to Alzheimer’s disease and affects more than 3 million ... continue reading